We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

By LabMedica International staff writers
Posted on 11 Jun 2021
Print article
Illustration
Illustration
The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population, technological improvements in point of care testing devices, and development of laboratory automation.

These are the latest findings of Verified Market Research (Lewes, Delaware, USA), a global research and consulting firm.

The increasing incidences of chronic diseases triggered largely due to lifestyle changes have been a key growth driver of the clinical chemistry analyzers market. A number of tests are carried out for the diagnosis of such diseases that gives a physician important insights into renal, cardiac and liver functions, among others. Thus, the growing prevalence of chronic diseases, especially diabetes, is expected to significantly contribute to the growth of the clinical chemistry analyzers market.

Another key growth driver of the clinical chemistry analyzers market is the rise in geriatric population around the world. The high geriatric population makes it vulnerable to contracting numerous age-associated chronic diseases that require efficient diagnosis, thus leading to the growth of the global clinical chemistry analyzers market.

However, COVID-19 has had a negative impact on the clinical chemistry analyzers market. Due to the ongoing lockdowns, people have been forced to stay indoors, and this restricted movement has slowed down the pace of testing, hence hampering market growth. Additionally, high initial setup costs and shortage of skilled laboratory technicians create further expenses for maintenance of equipment, which further hinders market growth. Nevertheless, increasing government support in the area of diagnostics, coupled with technological advancements, will provide further growth opportunities in the global clinical chemistry analyzers market.

Geographically, North America holds the highest share of the global clinical chemistry analyzers market and is expected to maintain its dominant position throughout the forecast period due to the presence of globally leading market players, technological leadership and an established healthcare infrastructure in the region. The Asia Pacific region is expected to register the highest CAGR in the forecast period, with countries such as China and Japan increasing their expenditure on healthcare facilities. This, coupled with a growing geriatric population and rapid technological growth, will be the key growth drivers of the clinical chemistry analyzers market in Asia Pacific.

Related Links:
Verified Market Research

New
Gold Supplier
INFLUENZA A/B RAPID TEST
COMBO INFLUENZA A+B-CHECK-1
New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
Gold Supplier
Microplate Washer
MW-12A
New
Next-Generation Sequencing (NGS) Workstation
NGS STAR for COVID-19

Print article
BIOHIT  Healthcare OY

Channels

Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.